Do you want to read an article? Please log in or register.
Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial
ARDS
RECOMMENDED
Related content
COMMENTED
ARDSAsthma
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial
Lancet Respir Med.
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials Group
doi: 10.1016/
RECOMMENDED
ARDS
Respiratory Mechanics and Outcomes in Immunocompromised patients with ARDS - A secondary analysis of the EFRAIM study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Demoule A, Antonelli M, Schellongowski P, Pickkers P, Soares M, Meyhoff T, Rello J, Bauer PR, van de Louw A, Lemiale V, Grimaldi D, Martin-Loeches I, Balik M, Mehta S, Kouatchet A, Barratt-Due A, Valkonen M, Reignier J, Metaxa V, Moreau AS, Burghi G, Mokart D, Mayaux J, Darmon M, Azoulay E, EFRAIM Investigators
doi: 10.1016/j.chest.2020.05.602.
RECOMMENDED
AsthmaCOPDPneumonia
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, Ni F, Fang S, Lu Y, Ding X, Liu H, Ewing RM, Jones MG, Hu Y, Nie H, Wang Y
doi: 10.1016/S2213-2600(21)00174-0
Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.
JAMA.
Kor DJ, Carter RE, Park PK, Festic E, Banner-Goodspeed VM, Hinds R, Talmor D, Gajic O, Ware LB, Gong MN; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A)
RECOMMENDED
Tuberculosis
Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis
Thorax.
Romanowski K, Balshaw RF, Benedetti A, Campbell JR, Menzies D, Ahmad Khan F, Johnston JC
doi: 10.1136/thoraxjnl-2017-211120.
Pneumonia
Fibroblast Growth Factor-21 Predicts Outcome in Community-Acquired Pneumonia Secondary Analysis of two Randomized Controlled Trials
Eur Respir J.
Ebrahimi F, Wolffenbuttel C, Blum CA, Baumgartner C, Mueller B, Schuetz P, Meier C, Kraenzlin M, Christ-Crain M, Betz MJ
doi: 10.1183/13993003.00973-2018.
RECOMMENDED
COPD
Association of Guideline-recommended COPD Inhaler Regimenswith Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1016/j.chest.2020.02.073.
RECOMMENDED
ARDS
Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Sinha P, Delucchi KL, McAuley DF, O'Kane CM, Matthay MA, Calfee CS
doi: 10.1016/S2213-2600(19)30369-8.
RECOMMENDED
COPD
Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Vogt S, Leuppi JD, Schuetz P, Mueller B, Volken C, Dräger S, Trendelenburg M, Rutishauser J, Osthoff M
doi: 10.1186/s12931-021-01822-9